上海APASL2017学术之旅中的必到“景点”（17日）

　　APASL2017的开幕式将在2月17日的上午8点举行。随后就将迎来本届会议的一个高潮——主席演讲和三场State-of-Art lecture演讲。接下来就是各细分领域的平行会议，转化医学课程，以及专题合作小组会议（SNG）。此外，最能反映一个会议学术水平的环节，最新研究成果的展示将陆续以大会报告、口头汇报、Late Breaking报告、青年研究者汇报和壁报等形式从今天陆续展开。最后，晚上举办的Culture Night也不要错过哦。

　　精彩报告如：

　　主席演讲

　　Clinical Network for Hepatitis B Cure and the Prevention of Mother-infant Transmission  

Jinlin HOU, Guangzhou

　　State-of-Art lecture演讲

　　01： Decision-Making in Hepatitis B: Integrating Guidelines, Research Data and Clinical Setting 

 Anna S.F. LOK, Ann Arbor

　　02：Microbiota and the Liver  

Lanjuan LI, Hangzhou

　　03：Novel Approches and Therapeutics in Acute on Chronic Liver Failure  

Shiv K. SARIN, New Delhi

　　Late Breaking报告

　　LB001  Hepatitis B Virologic Response and Resistance to Two Antiviral Therapy Regimens Among Hiv and Hbv Co-Infected Pregnant Women: Data from A Phase Ii Randomized Controlled Trial in Guangxi, China

　　LB002  Tenofovir Mono Rescue Therapy is Effective for Chronic Hepatitis B Patients with Multiple Nucleos(T)Ides Treatment Failure

　　LB003  Dual Mechanism of Actions of Novel Hbv Core Protein Allosteric Modifiers (Cpams): Inhibiting Viral Replication and Blocking cccDNA Formation

　　LB004  Correlation between Serum Hbv Rna , Hbv Dna, Hbsag, Hbeag and Lntrahepatic Cccdna at Baseline and 96 Weeks after Nucleos(T)Ide Analogues Treatment in Hbeag-Positive Patients with Chronic Hbv Infection

　　LB005  A Phase 3 Evaluation of Daclatasvir Plus Asunaprevir In Treatment-Naive Patients with Chronic HCV Genotype 1B Infection

　　LB006  Sustained Virological Response in Hcv Patients Treated with Daclatasvir + Sofosbuvir, With or Without Ribavirin: A Multicenter, Field-Practice Experience

　　LB007  Everest: Twelve-week Treatment Of Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin without Interferon Produces 100% SVR 12 in Treatment-Naive Chinese HCV Genotype 1 Patients without Cirrhosis

　　LB008  Relapse of Minimal Gepatic Encephalopathy After Treatment In Patients With Liver cirrhosis

　　LB009  Prevalence Of Pre-Treatment Ns5a And Ns5b Ni Resistance Associated Substitutions In HCV Infected Patients Enrolled In Clinical Trials In Asia

　　大会报告01

　　PL001  Impact of Baseline NS5A Polymorphisms on Sustained Virologic Response Rates to Treatment With Daclatasvir Plus Sofosbuvir with or without Ribavirin in Patients Infected with HCV Genotypes Prevalent in Asia

　　PL002  Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates with A Favorable Safety Profile in Asian Patients: An Integrated Subgroup Analysis of The ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies

　　PL003  Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients with Mild or Moderate Renal Impairment

　　PL004  High Efficacy in Patients with Chronic Hepatitis C Virus (HCV) Genotype (GT)1b Infection Treated with Elbasvir/Grazoprevir (EBR/GZR) for 12 Weeks: An Integrated Analysis

　　PL005ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection - A Randomized, Double-Blind, Placebo-Controlled Study

　　PL006  Statin Use Correlates with Reduced Risk of Pyogenic Liver Abscess: A Population- Based Case-Control Study

平行会议1：乙肝病毒诊断和治疗检测的生物标志物

平行会议2：肝衰竭：直接和具体的管理

平行会议3：炎症、微环境与肿瘤的发展

平行会议4：乙肝管理现状：未满足的需求和障碍

平行会议5：肝纤维化的分子机制：诊断和治疗

平行会议6：肿瘤干细胞与肝细胞癌

转化医学课程1：非病毒性肝炎

转化医学课程2：HCV——理想的丙型肝炎治疗方案

专题合作小组会议（SNG）1： 肝脏疾病的细胞免疫治疗

专题合作小组会议（SNG）2： 药物性肝损伤和肝脏的保护

专题合作小组会议（SNG）3： 肝脏病遗传学新方向

专题合作小组会议（SNG）4： 门静脉高压诊疗新技术